Teladoc's Short Interest Hits a Year High Before Thursday's Print

Among the closest digital health peers, short positioning on TDOC is the most crowded by a wide margin. Short interest has climbed to 18.3% of the free float, the highest reading in at least a year, while peers such as PHR, WAY and AMWL each saw one-week moves well under 2%. Teladoc's own shares rose 9.2% over the past week, a move that sits roughly 1.9 standard deviations above its typical weekly change, pulling in the opposite direction from a short book that grew 10.5% in the same period.

The scale of that short build is the defining feature of this setup. From mid-September through late October, short interest expanded by roughly 31% in a month. The most notable step-up came between October 22 and October 23, when positions jumped by more than three million shares in a single session. Borrow cost remains low at 0.53%, and availability is ample at 350%, meaning there are roughly 3.5 shares still available to lend for every one already borrowed. Nothing in the lending market is restricting the short side from adding further, and the squeeze pressure that sometimes accompanies elevated short interest is absent here.

Options positioning reinforces the same lean. The put/call ratio reached 0.48 on October 28, nearly 2.75 standard deviations above its 20-day average of 0.45. That is the most elevated reading in recent weeks, though the absolute level remains below 0.5, so call activity still dominates the book. The disconnect is worth noting: short sellers are piling in, yet options flow has not turned outright defensive. The stock's ORTEX short score of 67.0 ranks in the bottom 7th percentile of the broader universe, a reflection of how heavily the short positioning weighs on the composite.

The debate around Teladoc centres on its business model shift. The company is moving from subscription-based revenue toward a visit-based model, introducing volatility into what was once a more predictable revenue line. Membership declines in its Integrated Care segment, tied to health plan customer changes and the expiration of ACA subsidies, are the core bear concern. Bulls focus on the whole-person virtual care platform as a longer-term structural advantage. Analyst targets cluster around $7 to $10, a range that implies meaningful upside from the current $6.88 price, though those targets reflect actions taken in late July and August following last quarter's results, when multiple firms cut targets after the print. The most recent quarter's move tells its own story: the stock fell nearly 30% in one day after July's report.

Insider activity over the past 90 days has been net negative. The CEO sold shares in both September and October through open-market transactions not filed under a pre-arranged trading plan. The Chief Legal Officer and the Chief Accounting Officer also sold, while the BetterHelp president's sales were conducted under a 10b5-1 plan. Net insider selling over 90 days came to approximately 76,000 shares for a combined value near $485,000. On the institutional side, BlackRock added roughly 1.6 million shares as of September 30, and American Century added more than four million shares in the same period, making them among the more active accumulators recently.

Thursday's print will test whether Teladoc's revenue trajectory and any commentary on BetterHelp's commercial model shift can reconcile a short book near a one-year high with a stock that has already recovered 13% over the past month.